A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ Anstee QM Trauner M et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020;72:67A-68A. abstract 90.
- Ratziu V de Guevara L Safadi R et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized double-blind placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 701–800 of 830
MASLD-Related HCC: Trends, Pathogenesis and Current Treatment Options
Li, F., & Wu, Y. (2025) · Advances in Precision Medicine · doi:10.18063/apm.v10i2.896
“Lanifibranor (a pan-PPAR agonist) improves fibrosis in phase 2 [21] .”
Rebelos, E., & Kounatidis, D. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00273-9
The Ceiling Is Real: MASH Needs Combination, Not Celebration
Kumar, A., Sharma, P., & Arora, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103147
Kashyap, H., Kumari, J., & Khatri, M. (2025) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2025-0146
Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Zeb, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00023-8 · Cited by 1
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
UDFF and Auto‐ pSWE as Promising Noninvasive Biomarkers for MAFLD
Cao, J., Lu, A., & Chen, C. (2025) · Journal of Ultrasound in Medicine · doi:10.1002/jum.70075
Diabetes mellitus and hepatosteatosis: a narrative review
Kösekli, M. A. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101446
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetes aktuell · doi:10.1055/a-2665-1304
Non-Alcoholic Fatty Liver Disease (NAFLD): A Review of Risk Factors, Pathogenesis, and Treatment
李, 春. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113368
Metabolisch assoziierte Fettlebererkrankung (MASLD)
Kreimeyer, H., Gerken, G., & Canbay, A. E. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21164-5.00027-1
Trifylli, E.-M., Charalambous, C. H., Spiliotopoulos, N., Papadopoulos, N., Oikonomou, A., Manolakopoulos, S., & Deutsch, M. J. (2025) · Livers · doi:10.3390/livers5040065
“…GLP-1 agonists (e.g., Semaglutide) [110], SCD1 inhibitor (e.g., aramchol) [111], FXR agonists (e.g., Cilofexor or GS-9674) [112], and PPAR pan-agonists α , γ , δ (e.g., lanifibra-nor) [113] or dual PPAR α , δ agonist (e.g., elafibranor) [114], or dual PPAR α , γ agonist (e.g., Saroglitazar) [115].”
Naeeni, B., Ghaffari, F., Saki, S., Rashidi, M., Hatami, M., Shakerian, E., Ahangarpour, A., & Bavarsad, S. S. (2025) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp-166492
“These transcription factors, activated by specific ligands, are essential in controlling lipid metabolism and inflammatory processes (14).”
Puengel, T. (2023) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-39885
Uudet lääkkeet metabolisen rasvamaksataudin hoidossa
Huopalahti, A. (2025) · UTUPub (University of Turku)
Petroni, M. L. (2025) · The Journal of AMD · doi:10.36171/jamd25.28.3.16
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8383 · Cited by 3
Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights
Ghosh, S., Ghosh, A. J., Adhikari, M. D., Tiwary, B. K., & Saha, T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01861-3
MASH and the race for liver antifibrotics
Wills, Q. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2025.1704078 · Cited by 1
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Tailleux, A., & Kamel, S. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76568-0
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502639
Self-citationTowards a better detection of people with metabolic dysfunction-associated steatotic liver disease
Heyens, L. J. M. (2026) · Research Publications (Maastricht University) · doi:10.26481/dis.20260224lh
Yao, Y., Feng, J., Yue, H., Wu, J., Tong, M., Shi, X., Miao, Z., Wang, H., Qin, M., & Gong, P. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109764
Ong, J. P., Ghazinyan, H., Wong, V. W., & Eguchi, Y. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.006
Dunn, W., Krag, A. A., Kamath, P. S., & Singal, A. K. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.007
Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease
Li, X., Zhang, J., Wei, B., & Tong, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1775516 · Cited by 4
“However, adverse events such as nausea, diarrhea, and weight gain occurred more frequently in the lanifibranor groups (Francque et al., 2021).”
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01453-y
Bong, S. H. S., Teh, K. K., & Wong, V. W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0125 · Cited by 3
Topical delivery of a PPARγ agonist enables adipogenic repair of irradiated skin
Siegel, A. E., Hanumantharao, S. N., Koirala, P., Sehgal, V., He, C., Wu, M., Ghavimi, S. A. A., Chen, Z., Williams, Z., Xu, X., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201732
“18,19 20–23 Its robust pharmacologic profile made it a compelling candidate for repurposing in this context.”
Effect of nonalcoholic fatty liver disease on post-myocardial infarction cardiac remodeling
Biquard, L. (2022) · theses.fr (ABES) · doi:10.70675/4f4848d2z6a02z4576z9fc3zff58e2f5c501
Pathophysiologie der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung
Kantartzis, K. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01459-6
Rôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle
Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
Perspectives thérapeutiques de la modulation de PPAR-gamma dans les leucémies aiguës myéloïdes
Zhu, J. (2023) · theses.fr (ABES) · doi:10.70675/8a7b9621z18bez4cf1z9eadzab40e77e9c18 · Cited by 1
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH
Bernard, L. (2023) · theses.fr (ABES) · doi:10.70675/793b0b93z9794z42d4zb8dfz5f3d68268a9b
Rôle dépendant du sexe du récepteur constitutif aux androstanes CAR dans le métabolisme hépatique
Huillet, M. (2024) · theses.fr (ABES) · doi:10.70675/540eb301z7e1az46b2z8bc9z8e0347fb266a
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
Ageing liver in the era of MASLD: risks, mechanisms and treatment opportunities
Alqahtani, S. A., Schneider, C. V., & Schattenberg, J. M. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2026-103677
Self-citationNuevos horizontes en la comprensión de la disfunción metabólica asociada al hígado graso
Rubiano, J. F. M., Cardona, S. L., Betancur, S. S., & Rincón, A. R. (2026) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.13.1.911
“…actividad inflamatoria y la balonización) en alrededor del 45 % de los pacientes a 24 semanas, frente al 19 % con placebo, y también una mejoría ≥ 1 estadio de fibrosis en una proporción superior al placebo (aunque la diferencia en fibrosis no alcanzó significancia estadística en ese punto) (40).”
InfluentialDiabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
Munda, B., Bhutia, C., Deepti, & Khatri, M. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.011
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
“The results from the trial demonstrated a significantly greater percentage of patients with a decrease among those taking the 1200 mg dose of lanifibranor compared to the placebo, at 55% versus 33%, respectively (risk ratio 1.7, p = 0.007) [83].”
InfluentialHarnessing PPAR pharmacology through dual incretin-directed delivery
Petersen, J., & Clemmensen, C. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.009
When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble
Chen, Y., Ding, L., Zhao, S., Wang, W. B., Zhong, J., & Yan, Q. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70049
Adipose tissue inflammation: a main driver of metabolic dysfunction-associated steatohepatitis
Vachliotis, I. D., & Pοlyzos, S. A. (2026) · Immunometabolism · doi:10.1097/in9.0000000000000082
FlowTransOP: Distributional Translation of Omics Signatures via Constrained Deep Flow MatchingPreprint
Meimetis, N., Hoang, T. N., Magliacane, S., & Lauffenburger, D. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728305
“…dataset 40 , samples were obtained from healthy mice and mice under high fat diet (the CDAA-HFD mouse model), as well as CDAA-HFD mice treated with Lanifibranor, an investigational drug associated with MASH with promising results 41 , currently in a Phase 3 clinical trial (NCT04849728) 42 .”
Zhang, C.-Y., & Yang, M. (2026) · World Journal of Hepatology · doi:10.4254/wjh.120178
Yu, L.-Y., & Zhang, X. (2026) · World Journal of Hepatology · doi:10.4254/wjh.117543
Imaging findings of hepatic storage diseases
Rouilleault, A. C. I., Jiménez, S., Moreno, J. A., Belmonte, E., Ayuso, J. R., & García‐Criado, Á. (2026) · Radiología (English Edition) · doi:10.1016/j.rxeng.2026.101670
Pharmacologic management of metabolic and alcohol-associated liver disease
Pagadala, M., Jalil, S., Dunn, N., & Singal, A. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.29
“These include FGF21 analogs such as efruxifermin and pegozafermin [33] , PPAR agonist lanifibranor [53] , and Survodutide [54] .”
Hogerty, C., Zhao, Y., Wang, W., Weinman, S. A., & Zhong, W. (2026) · Biomolecules · doi:10.3390/biom16060895
Yang, Y., Zhang, F., Peng, Z., Wu, Y., Li, L., Shen, Z., Ye, Q., Yue, J., & Na, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.029
“It significantly improved histological features of MASH in Phase 2 trials 298,299 , and is currently undergoing Phase 3 evaluation.”
Lebererkrankungen als Komplikation des Diabetes mellitus
KAHL, S., & Huttasch, M. (2026) · Info Diabetologie · doi:10.1007/s15034-026-5273-x
“…Harn-drang aufgrund des erhöhten Glukosegehalts im Urin, der sowohl das Bakterien-und Pilzwachstum Lanifibranor ist ein pan-PPAR-Agonist in Phase III der klinischen Entwicklung für die Indikation der MASH und zeigte in einer Phase-II-Studie vor-teilhafte Effekte auf Entzündung und Fibrose [13].”
Wang, Q., Zhang, B., Wang, Y., Xu, X., Zuo, K., Luo, J., Fan, H., Li, Z., Pan, H., & Jiang, S. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09111
Santulli, G. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00321-4
“In phase 2b trials, lanifibra-nor at 1200 mg daily demonstrated resolution of NASH in 49% of treated patients versus 22% on placebo, supporting its advancement to the NATiV3 phase 3 trial [5].”
Khalil, I., Al-Badri, S. G., Hossain, M. S., Din, A. U., Ima, M. J., Rahman, M. T., Akter, M. M., Halder, L., Joy, A. D., Promi, S. A., et al. (2026) · Medicine · doi:10.1097/md.0000000000049493
“[90,91] However, the slower global rise than anticipated may indicate underreporting in LMICs or model adjustments in GBD 2023.”
Lee, J.-H., Yoo, J., Kim, S. G., & Kim, Y. S. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0043
Lonardo, A., Jamalinia, M., & Weiskirchen, R. (2026) · Livers · doi:10.3390/livers6050086 · Cited by 1
“Lanifibranor, a pan-peroxisome proliferation-activated receptor (PPAR) agonist targeting metabolic and inflammatory pathways, has also shown improvement in fibrosis in Phase 2b trials and continues to be evaluated in larger studies [180].”
Xu, H., Huang, G., Zhang, L., Liu, W., Wu, Q., Chen, M., Zhao, D., Zhang, Y., & Xu, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734643
Fu, H., & Saltiel, A. R. (2026) · Cell Research · doi:10.1038/s41422-026-01271-3
The Biological Clock–Mitochondria Axis in the Liver: From Molecular Mechanisms to Metabolic Disease
Manuti, V., Murgo, E., Saponaro, A. A., Sfregola, U., Sangineto, M., Villani, R., Serviddio, G., Mazzoccoli, G., & Colangelo, T. (2026) · Biology · doi:10.3390/biology15141197
“…for MASH, including the dual PPAR α / δ agonist elafibranor and the pan-PPAR agonist lanifibranor, may exhibit enhanced efficacy when administered during periods of increased hepatic fatty acid flux and β -oxidation demand, corresponding to the active phase of the circadian cycle [22,83].”
Zhao, R., Yang, J., Han, M., Tang, S., Hu, H., Guo, J., Ma, M., Sun, J., & Zhou, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146438
Lawitz, E., Poordad, F. F., & Goodman, Z. D. (2026) · Liver International · doi:10.1111/liv.70808
Pang, J., Do, L. N. H., Delgado, E., Zhao, J., Flynn, L., Liu, H. T., Autieri, M. V., Yang, X., & Liu, X. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107693
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1843719
Xiu, H., Li, T., Wen, J., Li, Z. B., Wu, J., Fu, X., Zhang, C., Yang, Z., Yao, X., & Xu, Z. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70416
MASLD: Spatial Mechanisms and New Therapeutics
Stoess, C., Onyuru, J., Hu, Y., Jiang, Y., Xin, Z., Panchal, A., & Hartmann, P. (2026) · Biomolecules · doi:10.3390/biom16081129
“The pan-PPAR agonist lanifibranor acts on metabolic, inflammatory, and fibrogenic pathways simultaneously and demonstrated histologic improvement in phase IIb studies [120].”
Melnikova, I., Karabanovich, G., Dušek, J., Ambrož, M., Laštůvková, H., Smutný, T., Bajnokova, M., Kamaraj, R., Salam, R., Reguli, A., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119458
Jain, R., Kaur, G., Grover, P., Yasin, Z., & Singh, B. (2026) · Livers · doi:10.3390/livers6040077
Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?
Weiskirchen, R., & Lonardo, A. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.62
Giannoukakis, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1901478
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
Socha, J. J., Pavithran, S., Burger, C. A., Karns, R. A., Lee, A., Lang, R. A., Moreno‐Fernandez, M. E., Standage, S. W., & VanDussen, K. L. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102429
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Du, Y., Qi, L., Shi, Y., Huang, X., Shi, X., Liu, M., Fang, Y., & Hu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1912000
MASLD pri asimptomatski odrasli populaciji
Perko, T. (2026) · Repository of the University of Primorsk (University of Primorska)
Paw, M., Minder, L., Laimbacher, A., Kaczara, P., Czepiec, M., Bobis‐Wozowicz, S., Wnuk, D., Kutryb-Zając, B. A., Braczko, A., Sarna, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.18.745414
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
“Beyond DNL-related targets, the pan-PPAR agonist lanifibranor has also shown potential for improving MASH activity and fibrosis in a phase 2b study, serving as an important addition to the metabolic nuclear receptor direction [64].”
Mu, Y., Zhu, W., Wei, Z., Guo, Z., Chen, H., Cheng, Y., & Zhou, W. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02991-4
“Several investigational or recently developed agents, including resmetirom, lani-fibranor, and obeticholic acid, have demonstrated histo - logical improvements in phase II–III clinical trials [18–20].”
Therapie metabolischer Lebererkrankungen: Lebensstilintervention, Chirurgie und Pharmakotherapie
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
New therapeutic options for metabolic‐associated steatotic liver disease
Straatmijer, T., & Mulder, M. B. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70795
Mahajan, N., Kaur, N., Sandhu, S. P. S., Patel, V., Boparai, H. K., Singh, K., & Singh, F. R. (2026) · Cureus · doi:10.7759/cureus.115501
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
“Despite a minor weight gain and peripheral edema, the multifaceted mode of action makes lanifibranor a promising candidate currently being evaluated in phase 3 trials [117].”
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177805
“The pan-PPAR agonist lanifibranor has also demonstrated improvements in steatohepatitis activity and fibrosis-related outcomes [41], whereas FXR agonists have shown metabolic and histological activity but their development has been constrained by adverse effects, including pruritus and unfavorable…”
Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917
“…( α / δ / γ ) agonist lan-ifibranor engages the same receptor family more broadly: in a phase 2b trial it significantly improved disease activity and fibrosis in non-cirrhotic NASH, with benefit observed regardless of diabetes status, being in present advancing through phase 3 development [175].”
Liu, H., Zhang, M., & Tacke, F. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s543657
“30,98 Farnesoid X Receptor (FXR) Agonists Farnesoid X receptor is a nuclear receptor that plays a central role in regulating bile acid, lipid, and glucose metabolism.”
Guo, M., Wu, Q., Deng, C.-H., Jiang, X., Wang, J. H., Zeng, C., Tan, X., Teng, F., Liu, Y., Zeng, Y., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156767
Passos, P. R. C., Filho, V. O. C., Moraes, B. D. F., Silveira, I. B., SÜFFERT, L. C., & Cançado, G. G. L. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.030
Leo, M., Cerchia, C., Laghezza, A., Rinaldi, F., Calleri, E., Colantuoni, V., Loiodice, F., Sabatino, L., & Lavecchia, A. (2026) · Biomolecules · doi:10.3390/biom16091316
“More recently, selected dual or pan-agonists, such as lanifibranor, have shown promising results in clinical studies in MASH, with Phase 3 evaluation ongoing [20,21].”
Yang, Y., Mu, M., Ren, K., Liu, H., Ma, P., Wang, Y., Zhang, M., Xu, X., Li, W., Gao, W., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71657
“Clinical evidence from a phase II NATIVE trial in patients with MASH demonstrated that lanifibranor significantly improved MASH and fibrosis after six months of treatment, with favorable tolerability [13].”
Research Progress in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease
蒋, 春. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693194
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
Context-Dependent Roles of Liver Macrophages in MASH
Horn, P., & Tacke, F. (2026) · Seminars in Liver Disease · doi:10.1055/a-2954-5433
Zhao, R., Zheng, J.-L., Wang, Y., Lu, B., Zhang, Y., & Deng, B.-C. (2026) · World Journal of Hepatology · doi:10.4254/wjh.124748
Jibran, K., Selestine, I., & Vernanda, S. (2026) · Eureka Herba Indonesia · doi:10.37275/ehi.v7i2.150
“10,22 In parallel, curcumin docked into AKT1 (ΔG = −8.8 kcal/mol), a hub governing hepatocyte survival and insulin signalling.”
Influential
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.